

Reply Form 回條

To: **Sinopharm Group Co. Ltd. *(the “Company”)**
(Stock Code: 01099)
c/o Computershare Hong Kong Investor Services Limited
(the “H Share Registrar”)
17M Floor, Hopewell Centre,
183 Queen’s Road East,
Wanchai, Hong Kong

致: **國藥控股股份有限公司 (「本公司」)**
(股份代號: 01099)
經香港中央證券登記有限公司
(「H 股登記處」)
香港灣仔皇后大道東 183 號
合和中心 17M 樓

I/We would like to receive the corporate communication of the Company[#] (the “Corporate Communication”) in the manner as indicated below:

本人/我們希望以下列方式收取 貴公司之公司通訊[#] (「公司通訊」):

(Please mark **ONLY ONE (X)** of the following boxes)

(請從下列選擇中, 僅在其中一個空格內劃上「X」號)

- to receive a notification letter informing that the Corporation Communication has been published on the Company’s website (www.sinopharmgroup.com.cn) and read the Corporate Communication published on the Company’s website (the “Website Version”) instead of receiving the printed copies; **OR**
收取有關公司通訊已在本公司網站(www.sinopharmgroup.com.cn)刊發之通知信函及在公司網站上瀏覽公司通訊 (「網上版本」), 以代替印刷本; **或**
- to receive the printed copies of all Corporate Communication in both English and Chinese versions; **OR**
收取所有公司通訊之中、英文印刷本; **或**
- to receive the printed copies of all Corporate Communication in English version only; **OR**
僅收取所有公司通訊之英文印刷本; **或**
- to receive the printed copies of all Corporate Communication in Chinese version only.
僅收取所有公司通訊之中文印刷本。

Contact telephone number
聯絡電話號碼

Signature
簽名

Date
日期

Notes:
附註:

- Please complete all your details.
請閣下填妥所有資料。
- If this Reply Form has not been received by the Company c/o the H Share Registrar by 27 May 2016, you are deemed to consent to receiving the Corporation Communication in the Website Version and we will only send to you a notification letter informing you that the Corporation Communication has been published on the Company’s website.
倘若本公司於 2016 年 5 月 27 日仍未通過 H 股登記處收到本回條, 閣下將被視為已同意以網上版本收取公司通訊, 而本公司將只向閣下寄發有關公司通訊已在本公司網站上刊發之通知信函。
- By selecting to read the Website Version of the Corporate Communication published on the Company’s website in place of receiving printed copies, you have expressly consented to waive the right to receive the Corporate Communication in printed form.
在選擇瀏覽在本公司網站發表之公司通訊網上版本以代替收取印刷本後, 閣下已明示同意放棄收取公司通訊印刷本的權利。
- If your shares are held in joint names, the shareholder whose name stands first on the register of members of the Company in respect of the joint holding should sign this Reply Form in order for it to be valid.
如屬聯名股東, 則本回條須由該名於本公司股東名冊上就聯名持有股份其姓名位列首位的股東簽署, 方為有效。
- The above instruction will apply to all Corporate Communication until you notify otherwise by reasonable notice in writing or by email at sinopharm.ecom@computershare.com.hk to the Company c/o the H Share Registrar.
上述指示適用於所有公司通訊, 直至閣下發出合理時間的書面通知或電郵到 sinopharm.ecom@computershare.com.hk 通過 H 股登記處予本公司, 另作選擇為止。
- Shareholders are entitled to change the choice of the language and/or means of receipt of the Corporate Communication at any time by reasonable notice in writing or by email at sinopharm.ecom@computershare.com.hk to the Company c/o the H Share Registrar.
股東有權隨時發出合理時間的書面通知或電郵到 sinopharm.ecom@computershare.com.hk 通過 H 股登記處予本公司, 要求更改收取公司通訊之語言版本及/或方式。
- For the avoidance of doubt, we do not accept any special instructions written on this Reply Form.
為免存疑, 任何寫在本回條上的額外指示, 本公司將不接受。

[#]Corporate Communication refers to any document issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.
公司通訊指本公司發出或將予發出以供其任何證券的持有人參照或採取行動的任何文件, 其中包括但不限於: (a)董事會報告、年度財務報表連同核數師報告及如適用, 財務摘要報告; (b)中期報告及如適用, 中期摘要報告; (c)會議通告; (d)上市文件; (e)通函; 及 (f)代表委任表格。

*The Company is registered as a non-Hong Kong company under Part XI of the Companies Ordinance (Chapter 32 of the Laws of Hong Kong) under its Chinese name and the English name “Sinopharm Group Co. Ltd.”
*本公司以其中文名稱及英文名稱“Sinopharm Group Co. Ltd.”根據香港法例第 32 章公司條例第 XI 部註冊為非香港公司。

SPGH-29042016-1(0)

閣下寄回此回條時, 請將郵寄標籤剪貼於信封上。

如在本港投寄毋須貼上郵票。

Please cut the mailing label and stick this on the envelope
to return this Reply Form to us.

No postage is necessary if posted in Hong Kong.

郵寄標籤 MAILING LABEL

香港中央證券登記有限公司
Computershare Hong Kong Investor Services Limited
簡便回郵號碼 Freepost No. 37
香港 Hong Kong